中文Laos BigBear Pharmaceuticals successfully obtained GMP certification for traditional medicine processing plants, improving product quality standards
Laos, October 7, 2023 - Laos BigBear Pharmaceuticals is pleased to announce that the company's traditional Chinese medicine processing plant successfully obtained GMP (Good Manufacturing Practice) certification. This certification marks that BigBear Pharmaceuticals' quality management level in the field of traditional medicine production has been internationally recognized, further improving product quality standards.
GMP certification is one of the important certifications in the pharmaceutical industry, aiming to ensure quality and safety during the drug manufacturing process. Obtaining GMP certification means that the traditional medicine processing plant meets a series of strict production standards and specifications, including requirements for equipment, personnel, processes, records and quality control. This will help ensure the consistency, stability and safety of TCM products.
BigBear Pharmaceuticals has always focused on quality management and product safety, and provides consumers with high-quality pharmaceutical products by continuously improving production processes and quality control systems. Obtaining GMP certification for a traditional medicine processing plant is an important milestone for the company's quality management system and further demonstrates its commitment and efforts to product quality.
Regarding this important certification, PANISA, CEO of BigBear Pharmaceuticals, said: "We are very proud to announce that our traditional medicine processing plant has obtained GMP certification. This is recognition of our strong commitment to quality management and the result of our continuous improvement of product quality. . We will continue to uphold the principles of high quality and safety to provide consumers with better drug choices."
The GMP certification of this traditional medicine processing plant will further enhance the competitiveness of BigBear Pharmaceuticals in domestic and foreign markets. As one of the largest pharmaceutical companies in Laos, the company has always been committed to meeting the needs of patients and consumers for high-quality drugs. Obtaining GMP certification will further enhance the company's reputation and credibility, and win the trust of more partners and customers for the company.
The success of this GMP certification is also an important boost to the development of the traditional medicine industry in Laos. With the improvement of the international recognition level of traditional medicine, it will help enhance the competitiveness of Lao traditional medicine in the international market and promote cooperation and exchanges between Laos and Laos in the international pharmaceutical field.
BigBear Pharmaceuticals will continue to strive to continuously improve product quality and safety standards and provide people with more efficient and safe traditional medicine products. The company will also continue to strengthen cooperation with regulatory agencies and relevant partners to jointly promote the development of the Lao traditional herbal medicine industry and make greater contributions to the health and well-being of the people.
About BigBear Pharmaceuticals:
BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.
Forward-Looking Statements:
Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.